La dYSfonCtion éreCtiLe / aCtuaLitéS 2011 et attitudeS thérapeutiQueS

Abstract

Phosphodiesterase Type V (IPDE5) Inhibitors are undoubtedly effective symptomatic treatments for Erectile Dysfunction (ED). But they do not treat its cause and do not prevent the underlying vascular disease from worsening, which will increase ED, and can lead to cardiovascular events.
serious, including fatal.
Obesity and Erectile Dysfunction. Central obesity (abdominal or visceral) is undoubtedly a factor in
independent risk for ED (level of evidence -NP- 1). It predicts its occurrence in each of the 5 prospective longitudinal studies that have been devoted to this association (particularly relative risk 1.9 in one
of them which included more than 22,000 men). It is also associated with it in the majority of cross-sectional studies. We know that obesity induces or worsens many risk factors for both ED and
cardiovascular disease, in the form of Metabolic Syndrome and each of its individual components.
It is also associated with disturbances in penile hemodynamics